Incorrect. CU6, which I have a parcel of, is doing ok and looks promising. CU6 trials are shorter and the payback potential is closer and more visible.
But it is correct that in general the spec biotech sector is getting hammered. No light at the end of the tunnel just yet. We need interest rates to stop rising for this sector to turn.
Overnight Market report, page-1447
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
31.0¢ |
Change
-0.010(3.13%) |
Mkt cap ! $450.9M | |||
| Open | High | Low | Value | Volume |
| 32.0¢ | 32.8¢ | 31.0¢ | $758.7K | 2.412M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 166349 | 31.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.5¢ | 312504 | 6 |
View Market Depth
| Last trade - 16.10pm 03/10/2024 (20 minute delay) ? |
| IMM (ASX) Chart |